WHO advises against obesity drugs and surgery for children under ten in first global guidance

Global guidance for young patients

The World Health Organization published its first global guidelines on managing obesity in children and adolescents, advising against prescribing weight-loss medications or performing bariatric surgery on children under ten years of age. The agency determined that the long-term health consequences of powerful glucagon-like peptide-1 (GLP-1) receptor agonists remain uncertain for young populations. GLP-1 drugs, originally developed for type 2 diabetes management under brand names such as Ozempic, Wegovy, and Mounjaro, mimic metabolic hormones to stimulate insulin production and promote satiety. Following its December 2025 recommendations supporting GLP-1 treatments for adults, the agency established distinct standards for youth. Although these drugs are primarily licensed for older age groups, off-label prescribing occurs, and pharmaceutical firms are testing the medications in pediatric trials involving children as young as six. The WHO stated that it does not oppose scientific drug trials, but insists routine clinical care for young children must exclude pharmaceutical and surgical interventions.

Strict conditions for adolescents

For adolescents between the ages of 10 and 19, the WHO guidelines restrict pharmacological treatment to specific fallback circumstances. Clinicians may consider authorized weight-loss drugs only when a supervised program combining dietary adjustments, physical exercise, and behavioral modifications fails to yield results over at least six months. Surgical interventions such as bariatric operations face even stricter limitations, reserved exclusively for adolescents suffering from severe obesity alongside complications such as hypertension or type 2 diabetes. According to Maria Nieves Garcia Casal from the WHO Department of Nutrition and Food Safety, surgery requires that the patient has completed physical and mental development and that non-invasive interventions have proved unsuccessful.

The foundation of obesity therapy for children and adolescents is not medication or surgery. Rather, it is about comprehensive support that enables healthy eating, physical activity, and sustainable behavior change.

Rising prevalence and health risks

The release of the guidance follows decades of steep growth in pediatric weight issues across the globe. According to WHO data, 170 million children and adolescents lived with obesity in 2024. This total comprises 70 million children in the 5 to 9 age bracket and 100 million young people in the 10 to 19 demographic.

Among youth aged 5 to 19, the global prevalence of obesity rose from 2% in 1990 to 8% in 2024. Luz Maria De Regil noted that while obesity rates continue to climb across all world regions, certain high-income nations have managed to slow the rate of expansion. The WHO outlined that pediatric obesity is a complex, chronic condition that increases vulnerability to cardiovascular diseases, metabolic disorders, and mental health difficulties, including anxiety, depression, low self-esteem, and social isolation.

Behavioral and digital interventions

The guidelines instruct health systems to move away from isolated weight metrics and focus on holistic, long-term well-being and functional health. Interventions must be tailored to the child's developmental stage and require active engagement from parents and family members to sustain lifestyle adjustments. On the technological front, the WHO reviewed limited available evidence and noted that digital tools, such as wearable activity monitors and active video games that encourage physical exercise, can play a constructive role in supporting behavioral changes. The agency concluded that clinical care pathways must be paired with broader public health policies, warning that medical therapies alone cannot curb the worldwide spread of childhood obesity.